Position in GRFS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,782
-$2,094 QoQ
Shares Held
393
-35.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#139
of 164 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026JONES FINANCIAL COMPANIES LLLP holds $2,915,385,555 across 19 Drug Manufacturers - General names. GRFS ranks #18 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
746,099 | $894,893,598 | |
| 2 | JNJ |
Johnson & Johnson
|
1,814,780 | $460,899,675 | |
| 3 | MRK |
Merck & Co., Inc.
|
2,548,737 | $327,512,704 | |
| 4 | AZN |
Astrazeneca PLC
|
1,670,876 | $316,831,506 | |
| 5 | NVS |
Novartis AG
|
1,974,043 | $309,372,018 | |
| 6 | ABBV |
AbbVie Inc.
|
988,813 | $248,824,903 | |
| 7 | PFE |
Pfizer Inc
|
4,638,683 | $111,699,485 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
502,809 | $63,524,888 |
All Filings in GRFS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,782 | 393 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $4,876 | 608 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,477 | 158 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,573 | 158 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $1,428 | 158 | Shares | Sole | 2025-08-13 | |
| 2024-12-31 | $171 | 23 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $204 | 23 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $145 | 23 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $153 | 23 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $265 | 23 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||